Broadcom named strategic vendor for Walmart virtualization solutions
RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX) reported better-than-expected first quarter results and raised its full-year revenue guidance on Monday.
The company saw its shares jump up 2.13% in premarket trading after the earnings release.
The biotechnology company posted Q1 adjusted earnings of $0.00 per share, beating analyst estimates of a $0.07 per share loss. Revenue surged 51% YoY to $134.2 million, exceeding the consensus forecast of $127.91 million.
BioCryst’s ORLADEYO, an oral treatment for hereditary angioedema (HAE), drove the strong performance with Q1 net revenue of $134.2 million, up 51% from the same period last year.
"We started 2025 with another quarter of outstanding performance. ORLADEYO revenue growth was driven by moving ORLADEYO patients from free drug to paid at a much faster rate than we expected," said Jon Stonehouse, president and CEO of BioCryst.
The company raised its full-year 2025 ORLADEYO revenue guidance to $580-600 million, up from its previous outlook of $535-550 million and above analyst projections of $563.6 million.
BioCryst now expects to achieve profitability in 2025, a year ahead of schedule. The company also paid down $75 million of debt, which it says will save approximately $23.5 million over the life of the loan.
In pipeline news, BioCryst submitted a new drug application to expand ORLADEYO’s label to children with HAE aged 2 to 11. The company also opened a U.S. investigational new drug application for BCX17725 to treat Netherton syndrome.
BioCryst ended the quarter with $317.3 million in cash and investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.